Novacyt partners with Applied Microarrays

The US partnership aims to facilitate the design and optimisation of customised microarray assays

Novacyt, an international specialist in clinical diagnostics, has announced that its molecular testing division, Primerdesign, has partnered with Applied Microarrays (AMI), a company that specialises in providing customised microarrays, manufacturing point-of-care (POC), high throughput DNA and protein arrays, to offer comprehensive single nucleotide polymorphism (SNP) assay development.

Primerdesign will play an integral part in designing probes for AMI and their customers. The microarray based molecular diagnostic tests developed under this partnership will play a crucial role in the early diagnosis, as well as improve patient management and outcome.

Alastair Malcolm, President and CEO of AMI, commented: “Through working with Primerdesign, we have been impressed with their assay development expertise and ability to deliver a high quality service in a timely manner. I am confident that our partnership will help us to deliver multiplexed probe based diagnostic and detection with better diagnosis and improved patient outcomes.”

Primerdesign has 13 years of experience in molecular assay design and this partnership highlights the division’s pivotal role in assay development as it grows its relationships with leading diagnostic companies.

Working together, Primerdesign and AMI can provide a full suite of assay development services from probe designs, through to assay optimisation, regulatory and ultimately high volume manufacturing of SNP microarrays for use in POC as well as laboratory-based settings.

Graham Mullis, Group CEO of Novacyt, added: “I am delighted that we are entering into a partnership with AMI. This partnership significantly expands our offering and geographic reach as we continue to expand our molecular products business."

“I am also pleased to see continued progress in our business-to-business opportunities converting into commercial partnerships. We are increasingly becoming the partner of choice for molecular diagnostic companies and I look forward to updating shareholders with further partnerships like this.”

Financial terms of the agreement have not been disclosed.

Companies